IBJNews

Lilly collaboration with outside researchers yields first deal

Back to TopCommentsE-mailPrintBookmark and Share

Indianapolis-based Eli Lilly and Co. has struck its first deal under an open-collaboration program launched last year to evaluate the potential of compounds synthesized in university and biotech labs.

After receiving data on more than 30,000 compounds from researchers in 26 countries, the first collaborative agreement was reached in its own back yard, with University of Notre Dame researchers Marvin Miller and Garrett Moraski.

They‘ll work with Lilly scientists for at least the next year to discover the potential of the Notre Dame compounds to starve the blood flow to tumors.

While there’s nothing new about collaborations with outside researchers, Lilly’s Phenotypic Drug Discovery Initiative, or PD2, is to provide a more convenient entry point for outside researchers into Lilly’s drug-discovery and -development process.

It allows the drugmaker to establish relationships with outside scientists that may not have worked with Lilly before. The ultimate goal is finding a promising compound, which an outside researcher might otherwise leave on the shelf, and turn it into the next blockbuster drug.

PD2 consists of a secure Web portal that researchers use to submit the structure of their compounds for an initial computational analysis by Lilly. If it shows promise, a researcher is invited to submit a biological sample for testing.

The outside researchers receive more extensive data on the compound’s biological profile than what generally is possible in academic or government labs, Lilly says.

In return, Lilly gets first rights to exclusively negotiate a collaboration or licensing agreement.

“This is the first of many” collaborations to be formalized in the months ahead, said Alan Palkowitz, vice president of discovery chemistry research and technologies at Lilly.

Lilly has about 70 of its own compounds in the pipeline at its labs worldwide. As research and development costs have risen, Lilly and its competitors have been forging alliances with outside companies—licensing their technologies or outright buying the firms.

The PD2 program’s approach is believed to be unique among big drug companies. About two-thirds of interest in PD2 so far has come from university researchers.

Traditionally, a pharmaceutical company might buy technology from a university lab and the relationship might end then and there, Notre Dame’s Miller said.

He says Lilly’s approach goes beyond a financial transaction in that his team has received valuable data from Lilly – 90-some pages from the analysis of Notre Dame’s compound that originally was synthesized to treat tuberculosis.

“The intricacy of the data was really rich from a researcher’s point of view,” said Miller’s colleague, Moraski.

Such data can be used as part of further research and can improve the odds of a researcher's landing a federal grant, as well.

“Our upfront transaction currency is not money. It’s actually data,” said Lilly’s Palkowitz.

The Notre Dame researchers will work directly with Lilly scientists for the at least the next year, something Moraski, who is passionate about finding ways to combat cancer, finds rewarding as well.

Such collaborations help Lilly leverage the expensive investment it has made over the years in its assay system to evaluate compounds to treat Alzheimer’s disease, cancer, diabetes and osteoporosis.

One of Lilly’s best-known products, the cancer drug Alimta, stemmed from a collaboration with Princeton University researcher Edward C. Taylor. The drug rang up sales of more than $2 billion last year.

 

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. why oh why does this state continue to elect these people....do you wonder how much was graft out of the 3.8 billion?

  2. i too think this is a great idea. I think the vision and need is there as well. But also agree with Wendy that there may be better location in our city to fulfill this vision and help grow the sports of hockey and figure skating in Indy. Also to help further develop other parts of the city that seem often forgotten. Any of the other 6 townships out side of the three northernmost could benefit greatly from a facility and a vision like this. For a vision that sounds philanthropic, the location is appears more about the money. Would really like to see it elsewhere, but still wish the development the best of luck, as we can always use more ice in the city. As for the Ice growth when they return, if schedules can be coordinated with the Fuel, what could be better than to have high level hockey available to go see every weekend of the season? Good luck with the development and the return of the Ice.

  3. How many parking spaces do they have at Ironworks? Will residents have reserved spaces or will they have to troll for a space among the people that are there at Ruth Chris & Sangiovese?

  4. You do not get speeding ticket first time you speed and this is not first time Mr.Page has speed. One act should not define a man and this one act won't. He got off with a slap on the wrist. I agree with judge no person was injured by his actions. The state was robbed of money by paying too much rent for a building and that money could have been used for social services. The Page family maybe "generous" with their money but for most part all of it is dirty money that he obtained for sources that are not on the upright. Page is the kind of lawyer that gives lawyers a bad name. He paid off this judge like he has many other tine and walked away. Does he still have his license. I believe so. Hire him to get you confiscated drug money back. He will. It will cost you.

  5. I remain amazed at the level of expertise of the average Internet Television Executive. Obviously they have all the answers and know the business inside and out.

ADVERTISEMENT